Recombinant human monoclonal antibody expressed in CHO binding to human PDCD1. Nivolumab is a fully human IgG4 monoclonal antibody for the treatment of cancer. Nivolumab acts as an immunomodulator by blocking ligand activation of the programmed cell death 1 (PD-1) receptor on activated T cells.